参考文献/References:
[1]Lüneburg N,Harbaum L,Hennigs JK. The endothelial ADMA/NO pathway in hypoxia-related chronic respiratory diseases[J]. Biomed Res Int,2014,2014:50161.
[2]Chen K,Pittman RN,Popel AS. Nitric oxide in the vasculature:where does it come from and where does it go? A quantitative perspective[J]. Antioxid Redox Signal,2008,10(7):1185-1198.
[3]Moraga FA,Miranda G,López V,et al. Chronic intermittent hypobaric hypoxia (4 600 m) attenuates pulmonary vasodilation induced by acetylcholine or sodium nitroprusside[J]. High Alt Med Biol,2018,19(2):149-155.
[4]Pera T,Zuidhof AB,Smit M,et al. Arginase inhibition prevents inflammation and remodeling in a guinea pig model of chronic obstructive pulmonary disease[J]. J Pharmacol Exp Ther,2014,349(2):229-238.
[5]López V, Moraga FA, Llanos AJ,et al. Plasmatic concentrations of ADMA and homocystein in llama (lama glama) and regulation of arginase typeⅡ:an animal resistent to the development of pulmonary hypertension induced by hypoxia[J]. Front Physiol,2018,9:1-10.
[6]Mizuno S,Ishizaki T,Toga H,et al. Endogenous asymmetric dimethylarginine pathway in high altitude adapted yaks[J]. Biomed Res Int,2015,2015:1-6.
[7]Lüneburg N,Siques P,Brito J,et al. Long-term chronic intermittent hypobaric hypoxia in rats causes an imbalance in the asymmetric dimethylarginine/nitric oxide pathway and ROS activity:a possible synergistic mechanism for altitude pulmonary hypertension?[J]. Pulm Med,2016,2016:1-9.
[8]Luks AM,Swenson ER,Bartsch P. Acute high-altitude sickness[J]. Eur Respir Rev,2017,26(143):1-14.
[9]Bartsch P,Swenson ER. Clinical practice:acute high-altitude illnesses[J]. N Engl J Med,2013,368(24):2294-2302.
[10]López V,Siques P,Brito J,et al. Upregulation of arginase expression and activity in hypertensive rats exposed to chronic intermittent hypobaric hypoxia[J]. High Alt Med Biol,2009,10(4):373-381.
[11]Brito J,Siques P,Arribas SM,et al. Adventitial alterations are the main features in pulmonary artery remodeling due to long-term chronic intermittent hypobaric hypoxia in rats[J]. Biomed Res Int,2015,2015:1-9.
[12]Scott JA,Duongh M,Young AW,et al. Asymmetric dimethylarginine in chronic obstructive pulmonary disease (ADMA in COPD)[J]. Int J Mol Sci,2014,15(4):6062-6071.
[13]Shivkar RR,Abhang SA. Ratio of serum asymmetric dimethyl arginine(ADMA)/nitric oxide in coronary artery disease patients[J]. J Clin Diagn Res,2014,8(8):CC04-CC06.
[14]Lee M,Rey K,Besler K,et al. Immunobiology of nitric oxide and regulation of inducible nitric oxide synthase[J]. Results Probl Cell Differ,2017,62:181-207.
[15]Blitzer ML,Lee SD,Creager MA. Endothelium-derived nitric oxide mediates hypoxic vasodilation of resistance vessels in humans[J]. Am J Physiol,1996,271(3Pt2):H1182-H1185.
[16]Song MY,Zwemer CF,Whitesall SE,et al. Acute and conditioned hypoxic tolerance augmented by endothelial nitric oxide synthase inhibition in mice[J]. J Appl Physiol(1985),2007,102(2):610-615.
[17]Luneburg N,Siques P,Brito J,et al. Long-term intermittent exposure to high altitude elevates asymmetric dimethylarginine in first exposed young adults[J]. High Alt Med Biol,2017,18(3):226-233.
[18]Sat?m?#351o?u H,Ozhan H,Albayrak S,et al. Relation of asymmetric dimethylarginine levels with conventional risk score systems in the healthy subjects with positive family history for coronary artery disease[J]. Anadolu Kardiyol Derg,2011,11(2):114-118.
[19]Jacobi J,Maas R,Arend M,et al. Effect of lowering asymmetric dimethylarginine(ADMA) on vascular pathology in atherosclerotic ApoE-deficient mice with reduced renal mass[J]. Int J Mol Sci,2014,15(4):5522-5535.
[20]Siques P,Brito J,Schwedhelm E,et al. Asymmetric dimethylarginine at sea level is a predictive marker of hypoxic pulmonary arterial hypertension at high altitude[J]. Front Physiol,2019,10:1-11.
[21]Vögeli A,Ottiger M,Meier MA,et al. Asymmetric dimethylarginine predicts long-term outcome in patients with acute exacerbation of chronic obstructive pulmonary disease[J]. Lung,2017,195(6):717-727.
[22]Scott JA,North ML,Rafii M,et al. Asymmetric dimethylarginine is increased in asthma[J]. Am J Respir Crit Care Med,2011,184(7):779-785.
[23]Vogeli A,Ottiger M,Meier MA,et al. Admission levels of asymmetric and symmetric dimethylarginine predict long-term outcome in patients with community-acquired pneumonia[J]. Respir Res,2017,18(1):1-12.
[24]崔源源,王欣,刘剑刚,等. 肿瘤坏死因子-α通过内皮型一氧化氮合酶和小凹蛋白-1介导内皮细胞功能失调的研究[J].心血管病学进展,2016,37(6):625-628.
[25]Pernow J,Jung C. Arginase as a potential target in the treatment of cardiovascular disease:reversal of arginine steal?[J]. Cardiovasc Res,2013,98(3):334-343.
[26]Durante W. Role of arginase in vessel wall remodeling[J]. Front Immunol,2013,4:1-12.
[27]Siques P,López de Pablo AL,Brito J,et al. Nitric oxide and superoxide anion balance in rats exposed to chronic and long term intermittent hypoxia[J]. Biomed Res Int,2014,2014:1-10.
[28]Klinger JR,Kadowitz PJ. The nitric oxide pathway in pulmonary vascular disease[J]. Am J Cardiol,2017,120(8S):S71-S79.
相似文献/References:
[1]马淑青 唐其柱.氧化应激在脓毒症心肌病中的研究进展[J].心血管病学进展,2021,(2):118.[doi:10.16806/j.cnki.issn.1004-3934.2021.02.006]
MA Shuqing,TANG Qizhu.Role of Oxidative Stress in Septic Cardiomyopathy[J].Advances in Cardiovascular Diseases,2021,(9):118.[doi:10.16806/j.cnki.issn.1004-3934.2021.02.006]
[2]石玉姣 熊双 刘春秋 杨晨光 董国菊 刘剑刚.射血分数保留性心力衰竭潜在的分子机制及治疗靶点[J].心血管病学进展,2022,(5):423.[doi:10.16806/j.cnki.issn.1004-3934.2022.05.010]
SHI Yujiao,XIONG Shuang,LIU Chunqiu,et al.Potential Molecular Mechanisms and Therapeutic Target in Heart Failure with Preserved Ejection Fraction[J].Advances in Cardiovascular Diseases,2022,(9):423.[doi:10.16806/j.cnki.issn.1004-3934.2022.05.010]
[3]王超 张先军 谢清梦 李丹 陈宽琴 李凤 余思芸 曾健 刘建.高海拔地区居民心电图特征的研究进展[J].心血管病学进展,2024,(11):1028.[doi:10.16806/j.cnki.issn.1004-3934.2024.11.015]
WANG Chao,ZHANG Xianjun,XIE Qingmeng,et al.Electrocardiographic Characteristics of Residents in High Altitude Areas[J].Advances in Cardiovascular Diseases,2024,(9):1028.[doi:10.16806/j.cnki.issn.1004-3934.2024.11.015]